Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
AstraZeneca
US Army
Medtronic
Colorcon
Farmers Insurance
Express Scripts
Deloitte

Generated: August 17, 2018

DrugPatentWatch Database Preview

OCTREOSCAN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Octreoscan patents expire, and what generic alternatives are available?

Octreoscan is a drug marketed by Mallinkrodt Nuclear and is included in one NDA.

The generic ingredient in OCTREOSCAN is indium in-111 pentetreotide kit. There are twenty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indium in-111 pentetreotide kit profile page.

Summary for OCTREOSCAN
US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 3
Clinical Trials: 18
DailyMed Link:OCTREOSCAN at DailyMed
Drug patent expirations by year for OCTREOSCAN

US Patents and Regulatory Information for OCTREOSCAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for OCTREOSCAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ➤ Try a Free Trial ➤ Try a Free Trial
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ➤ Try a Free Trial ➤ Try a Free Trial
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ➤ Try a Free Trial ➤ Try a Free Trial
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Accenture
McKinsey
Merck
Fuji
AstraZeneca
Cantor Fitzgerald
Moodys
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.